Today: 21 May 2026
Browse Category

NYSE:JNJ 6 February 2026 - 18 May 2026

Johnson & Johnson Shares Drop Friday, Week Ahead in Focus

Johnson & Johnson Shares Drop Friday, Week Ahead in Focus

Johnson & Johnson shares fell 1.77% to $226.71 Friday amid a broad market selloff but ended the week up about 2.4%. The NYSE is closed for the weekend, with trading set to resume Monday. Investors are watching upcoming neuropsychiatry data presentations and the global launch of the Shockwave C2 Aero Coronary IVL Catheter. No new earnings report is expected next week.
16 May 2026
·
Dow Jones Today: Why The Dow Is Holding Up While Nasdaq Sinks On AI Worries

Dow Jones Today: Why The Dow Is Holding Up While Nasdaq Sinks On AI Worries

The Dow rose 100.62 points to 49,268.41 on Tuesday, lifted by gains in Coca-Cola and Johnson & Johnson, while the S&P 500 fell 0.64% and the Nasdaq dropped 1.24% as investors sold AI-linked shares. Coca-Cola reported Q1 net revenue up 12% and raised its full-year earnings forecast. Nvidia, AMD, and Arm all declined sharply. Brent crude hovered near $111 amid U.S.-Iran tensions and OPEC uncertainty.
28 April 2026
·······
Johnson & Johnson Earnings Beat Estimates, J&J Raises 2026 Outlook Despite Stelara Slump

Johnson & Johnson Earnings Beat Estimates, J&J Raises 2026 Outlook Despite Stelara Slump

Johnson & Johnson reported first-quarter revenue of $24.1 billion, up 9.9%, and adjusted earnings of $2.70 per share, both above analyst estimates. Sales of cancer drug Darzalex hit $4 billion, while Stelara fell 60% to $656 million. The company raised its 2026 outlook, nudging full-year sales guidance to $100.8 billion. J&J shares slipped 0.27% to $237.96 in early trading.
14 April 2026
···
Johnson & Johnson Moves Tecvayli Earlier in Europe After FDA Myeloma Nod

Johnson & Johnson Moves Tecvayli Earlier in Europe After FDA Myeloma Nod

Johnson & Johnson filed with the European Medicines Agency to expand Tecvayli’s use as a solo treatment for adults with relapsed or refractory multiple myeloma after one prior therapy. The filing follows U.S. approval of Tecvayli with Darzalex last week and is supported by a phase 3 trial showing Tecvayli reduced disease progression or death by 71% versus standard care.
10 March 2026
···
Johnson & Johnson stock price slips as FDA fast-tracks nipocalimab; what investors watch next

Johnson & Johnson stock price slips as FDA fast-tracks nipocalimab; what investors watch next

Johnson & Johnson shares fell 0.7% to $245.07 Wednesday after its lupus drug nipocalimab received FDA Fast Track status. The stock lagged a broader market rally, with the S&P 500 ETF up nearly 1%. Investors weighed pipeline progress against ongoing legal risks and recent defensive trading. Johnson & Johnson will present at the Barclays Global Healthcare Conference on March 10.
4 March 2026
··
Arcellx stock surges toward $115 buyout price after Gilead deal sets new ceiling

Arcellx stock surges toward $115 buyout price after Gilead deal sets new ceiling

Arcellx shares surged 78% to $113.92 after Gilead Sciences agreed to acquire the company for $115 per share in cash, plus a $5 contingent payout tied to anito-cel sales, valuing Arcellx at up to $7.8 billion. The companies expect to close the deal in Q2 2026. Trading volume in Arcellx topped 11 million shares by mid-morning. Gilead shares fell 0.5%.
23 February 2026
····
Johnson & Johnson stock price: JNJ heads into Monday as Tremfya data lands and dividend date nears

Johnson & Johnson stock price: JNJ heads into Monday as Tremfya data lands and dividend date nears

Johnson & Johnson shares closed at $242.49 on Friday, down 1.8%. The company released new three-year Tremfya data in ulcerative colitis over the weekend. J&J stock goes ex-dividend Feb. 24, with a $1.30-per-share payout set for March 10. A potential $20 billion sale of its DePuy Synthes orthopedics unit remains under discussion.
22 February 2026
···
Johnson & Johnson stock price: JNJ heads into Monday with DePuy sale talk and Tremfya data

Johnson & Johnson stock price: JNJ heads into Monday with DePuy sale talk and Tremfya data

Johnson & Johnson shares fell 1.8% to $242.49 Friday after Reuters reported the company is preparing a potential $20 billion sale of its DePuy Synthes orthopedics unit. J&J released new long-term data for Tremfya in ulcerative colitis, showing 80.8% remission at week 140. The company did not comment on the reported DePuy sale. Investors await management updates in March and April.
21 February 2026
··
Johnson & Johnson stock price slips after hours as healthcare lags — what’s next for JNJ

Johnson & Johnson stock price slips after hours as healthcare lags — what’s next for JNJ

Johnson & Johnson shares fell 0.6% to $238.64 in after-hours trading Monday as healthcare stocks lagged, despite gains in the broader market. The company will present at the Barclays Global Healthcare Conference on March 10. J&J faces over 67,500 talc lawsuits, with a New Jersey court last week disqualifying a plaintiffs’ firm. The board declared a $1.30 quarterly dividend, with the stock going ex-dividend Feb. 24.
10 February 2026
·
Johnson & Johnson stock price: JNJ near 52-week high as talc ruling, heart-device data set up Monday

Johnson & Johnson stock price: JNJ near 52-week high as talc ruling, heart-device data set up Monday

A New Jersey appeals court disqualified Beasley Allen from representing plaintiffs in consolidated state talc cases against Johnson & Johnson; the firm plans to appeal. J&J shares closed up 0.93% at $239.99, near a 52-week high, before slipping slightly after hours. The company also reported positive pilot data for its investigational AFib platform.
8 February 2026
··
Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

Johnson & Johnson shares rose 0.9% to $239.99 Friday after a New Jersey appeals court disqualified Beasley Allen from state talc cases, citing improper coordination with a former J&J attorney. The ruling affects about 3,600 state lawsuits, while a related federal motion is pending. J&J also reported early 12-month pilot data for its investigational AFib device at a cardiology meeting.
7 February 2026
··
P&G stock price climbs in late trade as investors rotate to defensives — and an insider sale hits the tape

P&G stock price climbs in late trade as investors rotate to defensives — and an insider sale hits the tape

Procter & Gamble shares rose 1.1% to $158.61 in after-hours trading, outperforming broader market declines. CEO Ma. Fatima D. Francisco sold 8,000 shares at $158 each on Feb. 4, according to a regulatory filing. U.S. jobless claims increased to 231,000, while job openings fell to 6.542 million. P&G’s Gillette Venus announced a partnership with U.S. Figure Skating ahead of the Milano Cortina Winter Games.
6 February 2026
···
1 2 3 … 8

Stock Market Today

  • Highland Global Allocation Fund (HGLB) Ex-Dividend Date Set for May 22, 2026
    May 21, 2026, 11:21 AM EDT. Highland Global Allocation Fund (HGLB) will trade ex-dividend on May 22, 2026, for a monthly dividend of $0.085 payable May 29, 2026. This dividend represents approximately 1.04% of HGLB's recent price of $8.15. Historically, the stock has ranged between $7.53 and $10.64 over the past year, with a current estimated annualized yield of 12.52%. Shares are expected to open around 1.04% lower on the ex-dividend date, all else equal. HGLB shares traded down about 0.2% in Thursday trading, reflecting cautious market sentiment ahead of dividend payout.

Latest articles

Bloom Energy strikes $2.6 billion AI power deal amid grid bottleneck trade

Bloom Energy strikes $2.6 billion AI power deal amid grid bottleneck trade

21 May 2026
Nebius agreed to buy up to $2.6 billion in power capacity and electricity from Bloom fuel-cell systems over 10 years. Bloom shares rose 11.7% and Nebius climbed 16.8% after the announcement. The first project, replacing gas turbines, is expected to deliver 328 megawatts of installed capacity this year. Nebius will use Bloom’s on-site systems to speed up data center deployment.
Xanadu Jumps on $300 Million Capital Plan

Xanadu Jumps on $300 Million Capital Plan

21 May 2026
Xanadu shares rose as much as 8.9% Thursday after the Toronto company announced a $300 million equity facility and a quantum algorithm update. The Nasdaq-listed stock traded at $15.39, up $1.26, on volume of 3.1 million shares. The facility allows Xanadu to sell Class B shares over three years but does not require it. The announcement followed a sector rally sparked by new U.S. quantum funding.
GlobalFoundries shares jump after U.S. quantum funding news

GlobalFoundries shares jump after U.S. quantum funding news

21 May 2026
GlobalFoundries shares surged 12.7% to $79.75 after the company announced a $375 million letter of intent from the U.S. Department of Commerce to support quantum-chip manufacturing. Trading volume topped 3.4 million shares by mid-morning. The company also launched Quantum Technology Solutions and will pay its first quarterly dividend on July 14. The Nasdaq fell 0.4% in early trading.
Go toTop